Intercept

Quote


































































Do you have an RBD in the East with the last name Foley? What a tool this clown was at Takeda as a DM. Couldn’t sell ice if he was in the Sahara but he sure could look at your call reports and see when you made your first and last call. He finally must have gotten downsized with Takeda and now you get his leadership skills..........too bad.
 






Maximo609 said:
Do you have an RBD in the East with the last name Foley? What a tool this clown was at Takeda as a DM. Couldn’t sell ice if he was in the Sahara but he sure could look at your call reports and see when you made your first and last call. He finally must have gotten downsized with Takeda and now you get his leadership skills..........too bad.
Click to expand...

He sounds perfect!
 






Maximo609 said:
Do you have an RBD in the East with the last name Foley? What a tool this clown was at Takeda as a DM. Couldn’t sell ice if he was in the Sahara but he sure could look at your call reports and see when you made your first and last call. He finally must have gotten downsized with Takeda and now you get his leadership skills..........too bad.
Click to expand...

That is exactly the caliber of "leaders" this remedial organization is looking for-he will fit in perfectly.
 






Official AASLD PBC guidelines post meetings-Keith Lindor UDCA (ursodeoxycholic acid) remains first-line treatment for PBC. Biochemical response should be evaluated at 12 months to determine the need for second line therapy. For patients who do not respond to UDCA, OCA (obeticholic acid) is the only second-line therapy approved in the United States. “Fibrates can be considered as off-label alternatives to OCA,” he continued. “We are starting to see more and more data.” Itching is one area where fibrates are clearly superior to OCA, Dr. Lindor added. Where OCA has little or no effect on pruritis, fibrates can have very good effect.

Fibrates are the better option in PBC. <$, <itching & reported similar efficacy
 


















anonymous said:
Official AASLD PBC guidelines post meetings-Keith Lindor UDCA (ursodeoxycholic acid) remains first-line treatment for PBC. Biochemical response should be evaluated at 12 months to determine the need for second line therapy. For patients who do not respond to UDCA, OCA (obeticholic acid) is the only second-line therapy approved in the United States. “Fibrates can be considered as off-label alternatives to OCA,” he continued. “We are starting to see more and more data.” Itching is one area where fibrates are clearly superior to OCA, Dr. Lindor added. Where OCA has little or no effect on pruritis, fibrates can have very good effect.

Fibrates are the better option in PBC. <$, <itching & reported similar efficacy
Click to expand...

PBC and fibrates won’t kill you. Ocaliva might.
 












What is the deal with the severe itching? How many patients are stopping treatment? The sales growth for the PBC indication look very slow. If Gilead has a combo therapy coming out soon without the AEs, then this company is toast
 






Top Bottom
Back
Quote